Retour

Addex to Present at Bio€quity Europe 2024

News Press releases

Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.

GlobeNewswire Inc. • 08/05/2024 à 07:00:00
Addex Therapeutics Ltd American Depositary Shares
Website: https://www.addextherapeutics.com
Status: Active
Company Info

Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

List Date2020-01-29
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeADRC
Currency NameUSD
CIK0001574232
Composite figiBBG00R48ST95
Share Class figiBBG00R48SV18
Market Cap9,394,831 USD
Total Employees23
Share Class Shares Outstanding184350000
Weighted Shares Outstanding1068809
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
8.695
8.605
9.3
9.486
9.365
Variance
0.91%
-7.82%
-0.01%
1.32%
-0.21%
Open
8.617
9.335
9.301
9.362
9.385
Highest
8.83
9.335
9.391
9.615
9.57
Lowest
8.752
9.335
9.326
9.615
9.57
History
PeriodVarhighestlowest
1 week
-7.35%
9.57
8.752
1 month
-56.4%
20.329
8.725
3 month
-19.43%
14.786
8.725
6 month
42.78%
6.51
5
1 year
-42.03%
15.198
5
3 year
-95.67%
204
5
5 year
-97%
290
5
10 year
-97%
290
5
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
15:30
United States
-17800.000
15:30
United States
-60000.000
15:30
United States
53700.000
15:30
United States
-135800.000
★★
15:30
United States
4400.000
15:30
United States
215400.000
15:30
United States
-31400.000
15:30
United States
62600.000
15:30
United States
1300.000
15:30
United States
-9700.000
15:30
United States
199600.000
★★
15:30
United States
15:30
United States
15:30
United States
News Stream
News Press releases
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.
GlobeNewswire Inc. • 1w ago
News Press releases
Ad Hoc Announcement Pursuant to Art. 53 LR
GlobeNewswire Inc. • 2w ago
News Press releases
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland.
GlobeNewswire Inc. • 1mo ago
News Press releases
Ad Hoc Announcement Pursuant to Art. 53 LR
GlobeNewswire Inc. • 1mo ago
News Press releases
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
GlobeNewswire Inc. • 1mo ago
News Press releases
Addex receives CHF5M and 20% share of Neurosterix
GlobeNewswire Inc. • 1mo ago
News Press releases
Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of Discovery – Biology, will also be attending this event.
GlobeNewswire Inc. • 2mo ago
News Press releases
Ad Hoc Announcement Pursuant to Art. 53 LR
GlobeNewswire Inc. • 3mo ago
News Press releases
Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024.
GlobeNewswire Inc. • 4mo ago
News Press releases
CEO to provide update on allosteric modulator pipeline clinical and preclinical development
GlobeNewswire Inc. • 4mo ago
See All

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT